Global Benign Prostatic Hyperplasia Therapeutics Market Insights and Forecast to 2028

Report ID: 1750255 | Published Date: Jan 2025 | No. of Page: 113 | Base Year: 2024 | Rating: 4.1 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Alpha Blocker
        1.2.3 5-Alpha Reductase Inhibitor
        1.2.4 Phosphodiesterase-5 Inhibitor
        1.2.5 Others
    1.3 Market by Application
        1.3.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Mono Drug Therapy
        1.3.3 Combination Drug Therapy
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Benign Prostatic Hyperplasia Therapeutics Market Perspective (2017-2028)
    2.2 Benign Prostatic Hyperplasia Therapeutics Growth Trends by Region
        2.2.1 Benign Prostatic Hyperplasia Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Benign Prostatic Hyperplasia Therapeutics Historic Market Size by Region (2017-2022)
        2.2.3 Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Region (2023-2028)
    2.3 Benign Prostatic Hyperplasia Therapeutics Market Dynamics
        2.3.1 Benign Prostatic Hyperplasia Therapeutics Industry Trends
        2.3.2 Benign Prostatic Hyperplasia Therapeutics Market Drivers
        2.3.3 Benign Prostatic Hyperplasia Therapeutics Market Challenges
        2.3.4 Benign Prostatic Hyperplasia Therapeutics Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Benign Prostatic Hyperplasia Therapeutics Players by Revenue
        3.1.1 Global Top Benign Prostatic Hyperplasia Therapeutics Players by Revenue (2017-2022)
        3.1.2 Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Players (2017-2022)
    3.2 Global Benign Prostatic Hyperplasia Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Benign Prostatic Hyperplasia Therapeutics Revenue
    3.4 Global Benign Prostatic Hyperplasia Therapeutics Market Concentration Ratio
        3.4.1 Global Benign Prostatic Hyperplasia Therapeutics Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia Therapeutics Revenue in 2021
    3.5 Benign Prostatic Hyperplasia Therapeutics Key Players Head office and Area Served
    3.6 Key Players Benign Prostatic Hyperplasia Therapeutics Product Solution and Service
    3.7 Date of Enter into Benign Prostatic Hyperplasia Therapeutics Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Benign Prostatic Hyperplasia Therapeutics Breakdown Data by Type
    4.1 Global Benign Prostatic Hyperplasia Therapeutics Historic Market Size by Type (2017-2022)
    4.2 Global Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Type (2023-2028)
5 Benign Prostatic Hyperplasia Therapeutics Breakdown Data by Application
    5.1 Global Benign Prostatic Hyperplasia Therapeutics Historic Market Size by Application (2017-2022)
    5.2 Global Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Benign Prostatic Hyperplasia Therapeutics Market Size (2017-2028)
    6.2 North America Benign Prostatic Hyperplasia Therapeutics Market Size by Type
        6.2.1 North America Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2017-2022)
        6.2.2 North America Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2023-2028)
        6.2.3 North America Benign Prostatic Hyperplasia Therapeutics Market Share by Type (2017-2028)
    6.3 North America Benign Prostatic Hyperplasia Therapeutics Market Size by Application
        6.3.1 North America Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2017-2022)
        6.3.2 North America Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2023-2028)
        6.3.3 North America Benign Prostatic Hyperplasia Therapeutics Market Share by Application (2017-2028)
    6.4 North America Benign Prostatic Hyperplasia Therapeutics Market Size by Country
        6.4.1 North America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2017-2022)
        6.4.2 North America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2023-2028)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Benign Prostatic Hyperplasia Therapeutics Market Size (2017-2028)
    7.2 Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Type
        7.2.1 Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2017-2022)
        7.2.2 Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2023-2028)
        7.2.3 Europe Benign Prostatic Hyperplasia Therapeutics Market Share by Type (2017-2028)
    7.3 Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Application
        7.3.1 Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2017-2022)
        7.3.2 Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2023-2028)
        7.3.3 Europe Benign Prostatic Hyperplasia Therapeutics Market Share by Application (2017-2028)
    7.4 Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Country
        7.4.1 Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2017-2022)
        7.4.2 Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size (2017-2028)
    8.2 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Type
        8.2.1 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2023-2028)
        8.2.3 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Share by Type (2017-2028)
    8.3 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Application
        8.3.1 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2023-2028)
        8.3.3 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Share by Application (2017-2028)
    8.4 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Region
        8.4.1 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Benign Prostatic Hyperplasia Therapeutics Market Size (2017-2028)
    9.2 Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Type
        9.2.1 Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2017-2022)
        9.2.2 Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2023-2028)
        9.2.3 Latin America Benign Prostatic Hyperplasia Therapeutics Market Share by Type (2017-2028)
    9.3 Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Application
        9.3.1 Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2017-2022)
        9.3.2 Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2023-2028)
        9.3.3 Latin America Benign Prostatic Hyperplasia Therapeutics Market Share by Application (2017-2028)
    9.4 Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Country
        9.4.1 Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2017-2022)
        9.4.2 Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size (2017-2028)
    10.2 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Type
        10.2.1 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2023-2028)
        10.2.3 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Share by Type (2017-2028)
    10.3 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Application
        10.3.1 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2023-2028)
        10.3.3 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Share by Application (2017-2028)
    10.4 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Country
        10.4.1 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Abbott Laboratories
        11.1.1 Abbott Laboratories Company Details
        11.1.2 Abbott Laboratories Business Overview
        11.1.3 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Introduction
        11.1.4 Abbott Laboratories Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
        11.1.5 Abbott Laboratories Recent Developments
    11.2 Allergan plc
        11.2.1 Allergan plc Company Details
        11.2.2 Allergan plc Business Overview
        11.2.3 Allergan plc Benign Prostatic Hyperplasia Therapeutics Introduction
        11.2.4 Allergan plc Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
        11.2.5 Allergan plc Recent Developments
    11.3 Astellas Pharma
        11.3.1 Astellas Pharma Company Details
        11.3.2 Astellas Pharma Business Overview
        11.3.3 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Introduction
        11.3.4 Astellas Pharma Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
        11.3.5 Astellas Pharma Recent Developments
    11.4 Boehringer Ingelheim Pharma GmbH and Co. KG
        11.4.1 Boehringer Ingelheim Pharma GmbH and Co. KG Company Details
        11.4.2 Boehringer Ingelheim Pharma GmbH and Co. KG Business Overview
        11.4.3 Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Introduction
        11.4.4 Boehringer Ingelheim Pharma GmbH and Co. KG Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
        11.4.5 Boehringer Ingelheim Pharma GmbH and Co. KG Recent Developments
    11.5 Eli Lilly and Company
        11.5.1 Eli Lilly and Company Company Details
        11.5.2 Eli Lilly and Company Business Overview
        11.5.3 Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Introduction
        11.5.4 Eli Lilly and Company Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
        11.5.5 Eli Lilly and Company Recent Developments
    11.6 GlaxoSmithKline plc
        11.6.1 GlaxoSmithKline plc Company Details
        11.6.2 GlaxoSmithKline plc Business Overview
        11.6.3 GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Introduction
        11.6.4 GlaxoSmithKline plc Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
        11.6.5 GlaxoSmithKline plc Recent Developments
    11.7 Merck and Co.
        11.7.1 Merck and Co. Company Details
        11.7.2 Merck and Co. Business Overview
        11.7.3 Merck and Co. Benign Prostatic Hyperplasia Therapeutics Introduction
        11.7.4 Merck and Co. Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
        11.7.5 Merck and Co. Recent Developments
    11.8 Pfizer
        11.8.1 Pfizer Company Details
        11.8.2 Pfizer Business Overview
        11.8.3 Pfizer Benign Prostatic Hyperplasia Therapeutics Introduction
        11.8.4 Pfizer Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
        11.8.5 Pfizer Recent Developments
    11.9 Sanofi
        11.9.1 Sanofi Company Details
        11.9.2 Sanofi Business Overview
        11.9.3 Sanofi Benign Prostatic Hyperplasia Therapeutics Introduction
        11.9.4 Sanofi Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
        11.9.5 Sanofi Recent Developments
    11.10 Teva Pharmaceutical Industries Limited
        11.10.1 Teva Pharmaceutical Industries Limited Company Details
        11.10.2 Teva Pharmaceutical Industries Limited Business Overview
        11.10.3 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Introduction
        11.10.4 Teva Pharmaceutical Industries Limited Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
        11.10.5 Teva Pharmaceutical Industries Limited Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer

List of Tables
    Table 1. Global Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Alpha Blocker
    Table 3. Key Players of 5-Alpha Reductase Inhibitor
    Table 4. Key Players of Phosphodiesterase-5 Inhibitor
    Table 5. Key Players of Others
    Table 6. Global Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 7. Global Benign Prostatic Hyperplasia Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 8. Global Benign Prostatic Hyperplasia Therapeutics Market Size by Region (2017-2022) & (US$ Million)
    Table 9. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Region (2017-2022)
    Table 10. Global Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 11. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Region (2023-2028)
    Table 12. Benign Prostatic Hyperplasia Therapeutics Market Trends
    Table 13. Benign Prostatic Hyperplasia Therapeutics Market Drivers
    Table 14. Benign Prostatic Hyperplasia Therapeutics Market Challenges
    Table 15. Benign Prostatic Hyperplasia Therapeutics Market Restraints
    Table 16. Global Benign Prostatic Hyperplasia Therapeutics Revenue by Players (2017-2022) & (US$ Million)
    Table 17. Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Players (2017-2022)
    Table 18. Global Top Benign Prostatic Hyperplasia Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia Therapeutics as of 2021)
    Table 19. Ranking of Global Top Benign Prostatic Hyperplasia Therapeutics Companies by Revenue (US$ Million) in 2021
    Table 20. Global 5 Largest Players Market Share by Benign Prostatic Hyperplasia Therapeutics Revenue (CR5 and HHI) & (2017-2022)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Benign Prostatic Hyperplasia Therapeutics Product Solution and Service
    Table 23. Date of Enter into Benign Prostatic Hyperplasia Therapeutics Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2017-2022) & (US$ Million)
    Table 26. Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Type (2017-2022)
    Table 27. Global Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 28. Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Type (2023-2028)
    Table 29. Global Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2017-2022) & (US$ Million)
    Table 30. Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Application (2017-2022)
    Table 31. Global Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 32. Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Application (2023-2028)
    Table 33. North America Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2017-2022) & (US$ Million)
    Table 34. North America Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2023-2028) & (US$ Million)
    Table 35. North America Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2017-2022) & (US$ Million)
    Table 36. North America Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2023-2028) & (US$ Million)
    Table 37. North America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 38. North America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 39. Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2017-2022) & (US$ Million)
    Table 40. Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2023-2028) & (US$ Million)
    Table 41. Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2017-2022) & (US$ Million)
    Table 42. Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2023-2028) & (US$ Million)
    Table 43. Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 44. Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 45. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2017-2022) & (US$ Million)
    Table 46. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2023-2028) & (US$ Million)
    Table 47. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2017-2022) & (US$ Million)
    Table 48. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2023-2028) & (US$ Million)
    Table 49. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Region (2017-2022) & (US$ Million)
    Table 50. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Region (2023-2028) & (US$ Million)
    Table 51. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2017-2022) & (US$ Million)
    Table 52. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2023-2028) & (US$ Million)
    Table 53. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2017-2022) & (US$ Million)
    Table 54. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2023-2028) & (US$ Million)
    Table 55. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 56. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 57. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2017-2022) & (US$ Million)
    Table 58. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2023-2028) & (US$ Million)
    Table 59. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2017-2022) & (US$ Million)
    Table 60. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2023-2028) & (US$ Million)
    Table 61. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 62. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 63. Abbott Laboratories Company Details
    Table 64. Abbott Laboratories Business Overview
    Table 65. Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Product
    Table 66. Abbott Laboratories Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022) & (US$ Million)
    Table 67. Abbott Laboratories Recent Developments
    Table 68. Allergan plc Company Details
    Table 69. Allergan plc Business Overview
    Table 70. Allergan plc Benign Prostatic Hyperplasia Therapeutics Product
    Table 71. Allergan plc Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022) & (US$ Million)
    Table 72. Allergan plc Recent Developments
    Table 73. Astellas Pharma Company Details
    Table 74. Astellas Pharma Business Overview
    Table 75. Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Product
    Table 76. Astellas Pharma Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022) & (US$ Million)
    Table 77. Astellas Pharma Recent Developments
    Table 78. Boehringer Ingelheim Pharma GmbH and Co. KG Company Details
    Table 79. Boehringer Ingelheim Pharma GmbH and Co. KG Business Overview
    Table 80. Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Product
    Table 81. Boehringer Ingelheim Pharma GmbH and Co. KG Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022) & (US$ Million)
    Table 82. Boehringer Ingelheim Pharma GmbH and Co. KG Recent Developments
    Table 83. Eli Lilly and Company Company Details
    Table 84. Eli Lilly and Company Business Overview
    Table 85. Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Product
    Table 86. Eli Lilly and Company Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022) & (US$ Million)
    Table 87. Eli Lilly and Company Recent Developments
    Table 88. GlaxoSmithKline plc Company Details
    Table 89. GlaxoSmithKline plc Business Overview
    Table 90. GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Product
    Table 91. GlaxoSmithKline plc Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022) & (US$ Million)
    Table 92. GlaxoSmithKline plc Recent Developments
    Table 93. Merck and Co. Company Details
    Table 94. Merck and Co. Business Overview
    Table 95. Merck and Co. Benign Prostatic Hyperplasia Therapeutics Product
    Table 96. Merck and Co. Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022) & (US$ Million)
    Table 97. Merck and Co. Recent Developments
    Table 98. Pfizer Company Details
    Table 99. Pfizer Business Overview
    Table 100. Pfizer Benign Prostatic Hyperplasia Therapeutics Product
    Table 101. Pfizer Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022) & (US$ Million)
    Table 102. Pfizer Recent Developments
    Table 103. Sanofi Company Details
    Table 104. Sanofi Business Overview
    Table 105. Sanofi Benign Prostatic Hyperplasia Therapeutics Product
    Table 106. Sanofi Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022) & (US$ Million)
    Table 107. Sanofi Recent Developments
    Table 108. Teva Pharmaceutical Industries Limited Company Details
    Table 109. Teva Pharmaceutical Industries Limited Business Overview
    Table 110. Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Product
    Table 111. Teva Pharmaceutical Industries Limited Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022) & (US$ Million)
    Table 112. Teva Pharmaceutical Industries Limited Recent Developments
    Table 113. Research Programs/Design for This Report
    Table 114. Key Data Information from Secondary Sources
    Table 115. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Type: 2021 VS 2028
    Figure 2. Alpha Blocker Features
    Figure 3. 5-Alpha Reductase Inhibitor Features
    Figure 4. Phosphodiesterase-5 Inhibitor Features
    Figure 5. Others Features
    Figure 6. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Application: 2021 VS 2028
    Figure 7. Mono Drug Therapy Case Studies
    Figure 8. Combination Drug Therapy Case Studies
    Figure 9. Benign Prostatic Hyperplasia Therapeutics Report Years Considered
    Figure 10. Global Benign Prostatic Hyperplasia Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 11. Global Benign Prostatic Hyperplasia Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 12. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Region: 2021 VS 2028
    Figure 13. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Players in 2021
    Figure 14. Global Top Benign Prostatic Hyperplasia Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia Therapeutics as of 2021)
    Figure 15. The Top 10 and 5 Players Market Share by Benign Prostatic Hyperplasia Therapeutics Revenue in 2021
    Figure 16. North America Benign Prostatic Hyperplasia Therapeutics Market Size YoY (2017-2028) & (US$ Million)
    Figure 17. North America Benign Prostatic Hyperplasia Therapeutics Market Size Market Share by Type (2017-2028)
    Figure 18. North America Benign Prostatic Hyperplasia Therapeutics Market Size Market Share by Application (2017-2028)
    Figure 19. North America Benign Prostatic Hyperplasia Therapeutics Market Size Share by Country (2017-2028)
    Figure 20. United States Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 21. Canada Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 22. Europe Benign Prostatic Hyperplasia Therapeutics Market Size YoY (2017-2028) & (US$ Million)
    Figure 23. Europe Benign Prostatic Hyperplasia Therapeutics Market Size Market Share by Type (2017-2028)
    Figure 24. Europe Benign Prostatic Hyperplasia Therapeutics Market Size Market Share by Application (2017-2028)
    Figure 25. Europe Benign Prostatic Hyperplasia Therapeutics Market Size Share by Country (2017-2028)
    Figure 26. Germany Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. France Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. U.K. Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. Italy Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Russia Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Nordic Countries Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size YoY (2017-2028) & (US$ Million)
    Figure 33. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Size Market Share by Type (2017-2028)
    Figure 34. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Size Market Share by Application (2017-2028)
    Figure 35. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Size Share by Region (2017-2028)
    Figure 36. China Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. Japan Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. South Korea Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Southeast Asia Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. India Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Australia Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
    Figure 42. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size YoY (2017-2028) & (US$ Million)
    Figure 43. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size Market Share by Type (2017-2028)
    Figure 44. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size Market Share by Application (2017-2028)
    Figure 45. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size Share by Country (2017-2028)
    Figure 46. Mexico Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 47. Brazil Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 48. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size YoY (2017-2028) & (US$ Million)
    Figure 49. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Market Size Market Share by Type (2017-2028)
    Figure 50. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Market Size Market Share by Application (2017-2028)
    Figure 51. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Market Size Share by Country (2017-2028)
    Figure 52. Turkey Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 53. Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 54. UAE Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 55. Abbott Laboratories Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
    Figure 56. Allergan plc Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
    Figure 57. Astellas Pharma Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
    Figure 58. Boehringer Ingelheim Pharma GmbH and Co. KG Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
    Figure 59. Eli Lilly and Company Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
    Figure 60. GlaxoSmithKline plc Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
    Figure 61. Merck and Co. Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
    Figure 62. Pfizer Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
    Figure 63. Sanofi Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
    Figure 64. Teva Pharmaceutical Industries Limited Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
    Figure 65. Bottom-up and Top-down Approaches for This Report
    Figure 66. Data Triangulation
    Figure 67. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Abbott Laboratories
Allergan plc
Astellas Pharma
Boehringer Ingelheim Pharma GmbH and Co. KG
Eli Lilly and Company
GlaxoSmithKline plc
Merck and Co.
Pfizer
Sanofi
Teva Pharmaceutical Industries Limited
Frequently Asked Questions
Benign Prostatic Hyperplasia Therapeutics report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Benign Prostatic Hyperplasia Therapeutics report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Benign Prostatic Hyperplasia Therapeutics report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Coatings Resins

Coatings Resins market is segmented by Type and by Application. Players, stakeholders, and other  ... Read More

TMT Steel Bar

TMT Steel Bar market is segmented by Type and by Application. Players, stakeholders, and other pa ... Read More